Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.52 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613235 | 0.95 | OPRD1 (0.57) | ANPEPRNPEPDNPEPOPRD1OPRM1 | |
| SCHEMBL29613062 | 0.93 | LTA4H (0.53) | ANPEPRNPEPDNPEPOPRD1OPRM1 | |
| SCHEMBL29613047 | 0.92 | ANPEP (0.51) | ANPEPRNPEPDNPEPOPRD1OPRM1 | |
| SCHEMBL29613026 | 0.91 | OPRD1 (0.51) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29613063 | 0.90 | CTSK (0.53) | ANPEPRNPEPDNPEPOPRD1OPRM1 | |
| SCHEMBL29359869 | 0.90 | OPRD1 (0.57) | OPRD1OPRM1OPRK1CTSB | |
| SCHEMBL29434622 | 0.85 | OPRD1 (0.55) | OPRD1OPRM1OPRK1CTSB | |
| SCHEMBL30097100 | 0.84 | ANPEP (0.61) | ANPEPRNPEPDNPEPOPRD1OPRM1 | |
| SCHEMBL29613025 | 0.83 | OPRD1 (0.49) | ANPEPRNPEPDNPEPOPRD1OPRM1 | |
| SCHEMBL29362263 | 0.83 | OPRD1 (0.54) | OPRD1OPRM1OPRK1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590273-B2 | Stabilized glycoside hydrolase variants | NOVOZYMES A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-20250295120-A1 | CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION | NOVOZYMES A/S (DK) | 2025-09-25 | — | — | US | disclosed |
| US-12391934-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3953463-B1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES AS (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250084394-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2025-03-13 | — | — | US | disclosed |
| US-20250084346-A1 | ENCAPSULATED SOLID ENZYME PRODUCT | NOVOZYMES A/S (DK) | 2025-03-13 | — | — | US | disclosed |
| US-12129498-B2 | Stabilized endoglucanase variants | NOVOZYMES A/S (DK) | 2024-10-29 | — | — | US | disclosed |
| US-20240301328-A1 | POLYPEPTIDE VARIANTS | NOVOZYMES A/S (DK) | 2024-09-12 | — | — | US | disclosed |
| CN-118632931-A | Cleaning method, use of enzymes and cleaning composition | 诺维信公司 | 2024-09-10 | — | — | CN | disclosed |
| US-12060542-B2 | Polypeptides and compositions comprising such polypeptides | NOVOZYMES A/S (DK) | 2024-08-13 | — | — | US | disclosed |
| US-20240010955-A1 | Polypeptides and Compositions Comprising Such Polypeptides | NOVOZYMES A/S (DK) | 2024-01-11 | — | — | US | disclosed |
| EP-3704219-B1 | POLYPEPTIDES AND COMPOSITIONS COMPRISING SUCH POLYPEPTIDES | NOVOZYMES AS (DK) | 2024-01-10 | — | — | EP | disclosed |
| US-11767492-B2 | Methods of treating fabric using a Lactobacillus hexosaminidase | NOVOZYMES A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| US-20230295591-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2023-09-21 | — | — | US | disclosed |
| US-20230287380-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2023-09-14 | — | — | US | disclosed |
| US-11661592-B2 | Stabilized endoglucanase variants | NOVOZYMES A/S (DK) | 2023-05-30 | — | — | US | disclosed |
| US-20230143128-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | NOVOZYMES A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| US-11566239-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-20220411773-A1 | POLYPEPTIDES HAVING PROTEOLYTIC ACTIVITY AND USE THEREOF | NOVOZYMES A/S (DK) | 2022-12-29 | — | — | US | disclosed |
| US-20220186151-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES A/S (DK) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295120-A1 | CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION | DNASE1, HEXD, HEXA | ANPEP 45/4885RNPEP 27/4885DNPEP 63/4885 |
| US-20230143128-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | MGAM, MANBA, MAN2B1 | ANPEP 258/4885RNPEP 179/4885DNPEP 566/4885 |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | IDUA, IDE, TREH | ANPEP 28/4885RNPEP 129/4885DNPEP 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.